Supplementary Figure S10 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Supplementary Figure 10. Median overall survival (A) and progression-free survival (B) according to MAPK status excluding patients with oncogenic copy number variation. MAPK1/3-negative (yellow line; n = 41) vs MAPK1/3-positive (blue line; n = 33).